Peter Ulrichts
Company: Argenx
Job title: Scientific Lead Neuromuscular Franchise
Seminars:
Live Q&A 5:05 pm
day: Day One
Phase 3 Myasthenia Gravis Study of the FcRn Antagonist Efgartigimod 4:15 pm
• Brief overview of Myasthenia Gravis and diving into the novel mode of action of efgartigimod • Evaluating Phase 3 ADAPT trial design and redosing strategy based on patient symptoms, an individualized treatment approach • Assessing the safety and efficacy of efgartigimod in patients including secondary endpoints and prespecified analysesRead more
day: Day One